Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex

Nature Clinical Practice Nephrology

Volumn 2, Issue 2, 2006, Pages 92-100

  Michael, Beckie ^a,f   Fishbane, Steven ^b   Coyne, Daniel W ^c   Agarwal, Rajiv ^d   Warnock, David G ^e  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anemia; End stage renal disease; Intravenous iron; Iron deficiency; Sodium ferric gluconate complex

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; HEMOGLOBIN; IRON DEXTRAN; LIPOPOLYSACCHARIDE;

ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; BACKACHE; BACTERIAL GROWTH; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; ESCHERICHIA COLI; GLOMERULOSCLEROSIS; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON THERAPY; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY INJURY; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; VITAMIN SUPPLEMENTATION; VOMITING; WHEEZING;

FERRIC COMPOUNDS; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; RENAL DIALYSIS; SAFETY;

EID: 33644829151     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0068     Document Type: Review

References (63)

1. [No authors listed] (2001) NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 37 (Suppl 1): S182-S238
2. Wingard RL et al. (1995) Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25: 433-439
3. Markowitz GS et al. (1997) An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 28: 34-40
4. Fudin R et al. (1998) Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 79: 299-305
5. Besarab A et al. (1999) A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 34: 21-28
6. Centers for Medicare and Medicaid Services (2004) 2004 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Baltimore, MD: Department of Health and Human Services, Centers for Medicare and Medicaid Services, Office of Clinical Standards and Quality
7. Fishbane S et al. (1996) The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28: 529-534
8. Hamstra RD et al. (1980) Intravenous iron dextran in clinical medicine. JAMA 243: 1726-1731
9. Feridex® (ferumoxide injectible solution) label (Advanced Magnetics, Inc. 1997)
10. Faich G and Strobos J (1999) Sodium Ferric Gluconate Complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 33: 464-470
11. Fishbane S and Wagner J (2001) Sodium Ferric Gluconate Complex in the Treatment of Iron Deficiency for Patients on Dialysis. Am J Kidney Dis 37: 879-883
12. Ferrlecit® (sodium ferric gluconate complex in sucrose injection) package insert (Watson Pharmaceuticals 2004)
13. Seligman P et al. (2000) Fast IV Iron: Sodium ferric gluconate complex (SFGC) is Safe with No "Free" Iron Toxicity. J Am Soc Nephrol 11: A1560
14. Seligman PA et al. (2004) Single-Dose Pharmacokinetics of Sodium Ferric Gluconate Complex in Iron-Deficient Subjects. Pharmacotherapy 24: 574-583
15. Agarwal R (2004) Transferrin saturation with intravenous irons: An in vitro study. Kidney Int 66: 1139-1144
16. Venofer® (iron sucrose injection) package insert (American Reagent Labs 2004)
17. Parkkinen J et al. (2000) Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15: 1827-1834
18. Kooistra MP et al. (2002) Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 32 (Suppl 1): S36-S41
19. Danielson BG et al. (1996) Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 46: 615-621
20. Van Wyck D et al. (2004): Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 19: 561-565
21. Infed® (iron dextran injection) package insert (Watson Pharma, Inc. 2001)
22. Dexferrum® (iron dextran injection) package insert (American Reagent Labs 2001)
23. Panesar A and Agarwal R (2002) Safety and Efficacy of Sodium Ferric Gluconate Complex in Patients with Chronic Kidney Disease. Am J Kidney Dis 40: 924-931
24. Allegra V et al. (1991) Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 57: 175-182
25. Pascual J et al. (1991) Sodium ferric gluconate complex given intravenously for iron deficiency in hemodialysis. Clin Nephrol 35: 87
26. Navarro JF et al. (1996) Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients. Am J Nephrol 16: 268-272
27. Taylor JE et al. (1996) Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11: 1079-1083
28. Cortes MJC et al. (1997) Effect of intravenous Na-Fe-gluconate in hemodialysis patients treated with rHuEPO. Nefrologia 17: 424-429
29. Nissenson AR et al. (1999) Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis 33: 471-482
30. Michael B et al. (2002) Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 61: 1830-1839
31. Michael B et al. (2004) Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety. Nephrol Dial Transplant 19: 1576-1580
32. Schwartz LB et al. (1989) Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 83: 1551-1555
33. Schwartz LB et al. (1987) Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 316: 1622-1626
34. Coyne DW et al. (2003) Sodium ferric gluconate complex in hemodialysis patients: II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 63: 217-224
35. Rolla G et al. (1994) Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor. J Allergy Clin Immunol 93: 1074-1075
36. Parnes EL and Shapiro WB (1991) Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int 40: 1148-1152
37. Pegues DA et al. (1992) Anaphy lactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int 42: 1232-1237
38. Warady BA et al. (2005) Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol 20: 1320-1327
39. Folkert VW et al. (2003) Chronic use of sodium ferric gluconate complex (SFGC) in hemodialysis patients: safety of higher dose (≥250 mg) administration. Am J Kidney Dis 41: 651-617
40. Javier AM (2002) Weekly administration of high-dose sodium ferric gluconate is safe and effective in peritoneal dialysis patients. Nephrol Nurs J 29: 183-186
41. Kosch M et al. (2001) A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 16: 1239-1244
42. Esposito BP et al. (2002) Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 32 (Suppl 1): S42-S49
43. Sengoelge G et al. (2003) Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 14: 2639-2644
44. Patruta SI et al. (1998) Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9: 655-663
45. Zager RA et al. (2004) Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 65: 2108-2112
46. Feldman HI et al. (2004) Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15: 1623-1632
47. Zager RA et al. (2005) Parenteral iron compounds sensitize mice to injury-initiated TNF-α mRNA production and TNF-α release. Am J Physiol Renal Physiol 288: F290-F297
48. Zager RA et al. (2002) Parenteral Iron Formulations: A Comparative Toxicologic Analysis and Mechanisms of Cell Injury. Am J Kidney Dis 40: 90-103
49. Zager RA et al. (2004) Parenteral iron nephrotoxicity: Potential mechanisms and consequences. Kidney Int 66: 144-156
50. Roob JM et al. (2000) Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11: 539-549
51. Michelis R et al. (2003) Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 18: 924-930
52. Rooyakkers TM et al. (2002) Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32 (Suppl 1): S9-S16
53. Shah SV (2001) Role of iron in progressive renal disease. Am J Kidney Dis 37 (Suppl 1): S30-S33
54. Remuzzi A et al. (1991) Renoprotective effect of low iron diet and its consequence on glomerular hemodynamics. Kidney Int 39: 647-652
55. Nankivell BJ et al. (1992) Iron accumulation in human chronic renal disease. Am J Kidney Dis 20: 580-584
56. Alfrey AC et al. (1989) Role of iron in the tubulointerstitial injury in nephrotoxic serum nephritis. Kidney Int 36: 753-759
57. Leehey DJ et al. (2005) Sodium Ferric Gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrol Dial Transpl 20: 135-140
58. Agarwal R et al. (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65: 2279-2289
59. Sato K and Shiraki M (1998) Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocr J 45: 431-439
60. Besarab A (1999) Iron and cardiac disease in the end-stage renal disease setting. Am J Kidney Dis 34 (Suppl 2): S18-S24
61. Drueke T et al. (2002) Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212-2217
62. Boaz M et al. (2000) Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomized placebo-controlled trial. Lancet 356: 1213-1218
63. Tepel M et al. (2003) The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107: 992-995